


Drug Discovery

PRACTICES, PROCESSES,
AND PERSPECTIVES



EDITED BY
JIE JACK LI
E. J. COREY

Drug Discovery

Practices, Processes, and Perspectives

Edited by

Jie Jack Li

Bristol-Myers Squibb Company

and

E. J. Corey

Harvard University



 **WILEY**

A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2013 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey

Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data

Drug discovery : practices, processes, and perspectives / edited by Jie Jack Li, E.J. Corey.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-94235-2 (cloth)

I. Li, Jie Jack. II. Corey, E. J.

[DNLM: 1. Drug Discovery—methods. 2. Chemistry, Pharmaceutical—methods. QV 745]

615.1'9—dc23

2012032885

Printed in the United States of America.

10 9 8 7 6 5 4 3 2 1

Dedicated To
Professor Paul Floreancig

Preface

The primary audience of this book is scientists in drug discovery in general and novice medicinal chemists in particular. In academia, most of us are trained as synthetic organic chemists. It takes us many years to learn the trade of drug discovery “on-the-job.” This book is to jump-start our understanding of the landscape of drug discovery. Veteran medicinal chemists and process chemists will benefit from this book as well by learning the perspectives of drug discovery authored by experts in different fields of drug discovery.

We are indebted to contributing authors, all of whom are the world’s leading experts in drug discovery, for their hard work and care in writing definitive summaries of their respective fields. The pharmaceutical industry is going through an interesting time. We hope that this book will help all scientists in drug discovery appreciate the practices, processes, and perspectives of drug discovery.

Jack Li and E. J. Corey

August 1, 2012

Contributing Authors

Dr. Narendra B. Ambhaikar
Dr. Reddy's Laboratories
CPS
Bollaram Road, Miyapur
Hyderabad-500 049
Andhra Pradesh, India

Dr. Makonen Belema
Medicinal Chemistry
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Dr. Ana B. Bueno
DCR&T
Eli Lilly and Company
Avda de la Industria,
28108-Alcobendas
Madrid, Spain

Dr. Ana M. Castaño
DCR&T
Eli Lilly and Company
Avda de la Industria, 30
28108-Alcobendas
Madrid, Spain

Dr. Audrey Chan
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421, United States

Dr. Christopher W. Cianci
Virology
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Dr. Jason Cross
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421, United States

Dr. Stanley V. D'Andrea
Medicinal Chemistry
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Dr. Ira B. Dicker
Virology
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Dr. Jeremy J. Edmunds
Medicinal Chemistry
Abbott Bioresearch Center
381 Plantation St.
Worcester, MA, 01605, United States

Dr. Yong He
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421, United States

Dr. Adam R. Johnson
Biochemical Pharmacology
Genentech Inc.
1 DNA Way
South San Francisco, CA 94080
United States

Dr. Mark R. Krystal
Virology
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Dr. Kimberley Lentz
Metabolism and Pharmacokinetics
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Dr. Jie Jack Li
Medicinal Chemistry
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08540, United States

Dr. Blaise Lippa
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421, United States

Dr. John A. Lowe, III
JL3Pharma LLC
28 Coveside Lane
Stonington CT 06378, United States

Dr. Anthony M. Manning
Research & Preclinical Development
Aileron Therapeutics
281 Albany St.
Cambridge, MA 02139, United States

Dr. Nicholas A. Meanwell
Medicinal Chemistry
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Dr. Joseph Raybon
Metabolism and Pharmacokinetics
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Dr. Angel Rodríguez
Medical Affairs-Diabetes
Eli Lilly and Company
Avda de la Industria, 30
28108-Alcobendas
Madrid, Spain

Dr. M. Dominic Ryan
Cubist Pharmaceuticals, Inc.
65 Hayden Ave
Lexington, MA 02421, United States

Dr. Michael W. Sinz
Metabolism and Pharmacokinetics
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Dr. Drago R. Sliskovic
AAPharmasyn, LLC.
3985 Research Park Drive
Ann Arbor, MI 48108, United States

Dr. Kap-Sun Yeung
Medicinal Chemistry
Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, CT 06492, United States

Table of Contents

Chapter 1	History of Drug Discovery	1
Chapter 2	Target Identification and Validation	43
Chapter 3	<i>In Vitro</i> and <i>In Vivo</i> Assays	67
Chapter 4	Drug Metabolism and Pharmacokinetics in Drug Discovery	99
Chapter 5	Cardiovascular Drugs	141
Chapter 6	Diabetes Drugs	205
Chapter 7	CNS Drugs	245
Chapter 8	Cancer Drugs	287
Chapter 9	Anti-Inflammatory and Immunomodulatory Drugs	337
Chapter 10	Antibacterial Drugs	389
Chapter 11	Antiviral Drug Discovery	439
Index		517

Detailed Table of Contents

Chapter 1	History of Drug Discovery	1
1.	Introduction	1
2.	Antibacterials	1
2.1	Lister and Carbolic Acid	1
2.2	Dr. Ehrlich's Magic Bullet	2
2.3	Domagk and Sulfa Drugs	2
2.4	Fleming, Florey, Chain, and Penicillin	3
2.5	Waksman, Schatz, and Streptomycin	4
2.6	Duggar, Conover, and Tetracyclines	4
2.7	Quinolones and Zyvox	5
3.	Cancer Drugs	6
3.1	The Origin of Cancer	6
3.2	Chemotherapy	6
3.3	Hormone Treatment	8
3.4	Small-Molecule Protein Kinase Inhibitors	9
4.	Cardiovascular Drugs	10
4.1	Withering and Digitalis	11
4.2	Sobrero, Nobel, and Nitroglycerin	11
4.3	Vogl and Diuretics	12
4.4	Snake Venom and ACE Inhibitors	12
4.5	Black and Beta-Blockers	14
4.6	Renin Inhibitor	14
4.7	Fleckenstein and Calcium Channel Blockers	15
4.8	Blood Thinners, from Heparin to Plavix	16
5.	Cholesterol Drugs	17
5.1	Early Cholesterol Drugs: Niacin and Fibrates	17
5.2	Endo, Mevastatin, and Pravachol	18
5.3	Merck's Mevacor and Zocor	19
5.4	Lescol, Lipitor, Baycol, and Crestor	19
5.5	Zetia and Vytorin	21
6.	CNS Drugs	21
6.1	Sternbach, Valium, and Minor Tranquilizers	22
6.2	Antidepressants	22
6.3	Antipsychotics	24
6.4	Drugs for Epilepsy and Bipolar Disorder	25
7.	Anti-Inflammatory Drugs	26
7.1	Cortisone	26
7.2	Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)	27
7.3	Anti-asthmatics	28

8.	Antiulcer Drugs	30
8.1	James Black and the Discovery of Tagamet	30
8.2	Zantac, Pepcid, and Axid	30
8.3	Prilosec and Nexium	31
9.	Antiviral Drugs	33
9.1	Influenza Drugs	33
9.2	HIV Drugs	34
9.3	Hepatitis Virus Drugs	37
	References	38
Chapter 2 Target Identification and Validation		43
1.	Introduction	43
2	Definition of Drug Targets	43
3	Classification of Currently Utilized Drug Targets	45
4	Receptors as Drug Targets	46
4.1	G-Protein-Coupled Receptors	46
4.2	Ligand-Gated Ion Channels	47
4.3	Receptor Tyrosine Kinases	47
4.4	Nuclear Receptors	48
5	Enzymes as Drug Targets	48
6	Transporter Proteins as Drug Targets	49
7	Modern Technologies Employed in Target Identification and Validation	49
7.1	Human Genetics	50
7.2	Gene Family Mining	52
7.3	Gene Expression Profiling in Target Discovery	53
7.4	Proteomics	54
7.5	Oligonucleotides	56
7.6	Model Organisms	58
8	Impact of Therapeutic Modalities on the Selection Drug Targets	62
9	Future Directions	63
	References	63
Chapter 3 In Vitro and In Vivo Assays		67
1	Introduction	67
2	The Testing Funnel	67
3	<i>In Vitro</i> Assays	71
3.1	High-throughput Screening as a Source of Lead Matter	71
3.2	The IC ₅₀ as a Measure of Inhibitory Potency	73
3.3	Solubility	75
3.4	Nonspecific (Promiscuous) Inhibitors	76
3.5	Mechanism of Inhibition Studies	78

3.6	How to Identify Allosteric Inhibitors	82
3.7	Selectivity	83
3.8	Tight-binding Inhibition	84
3.9	Slow-Binding Inhibition, Reversibility, and Residence Time	86
3.10	Mechanism, Kinetics, and Potency Comparisons	89
3.11	Cell Assays	90
4	<i>In Vivo</i> Assays	92
4.1	Pharmacokinetics and Pharmacodynamics	92
4.2	Animal Models of Disease	95
4.3	Scaling Up	95
5	Outlook	96
	References	96

Chapter 4 Drug Metabolism and Pharmacokinetics in Drug Discovery

99

1	Introduction	99
2	Drug Metabolism	101
2.1	Drug-Metabolizing Enzymes	101
2.2	In Vitro and In Vivo Models to Evaluate Drug Metabolism	105
2.3	Metabolic Stability	107
2.4	Reaction Phenotyping	108
2.5	Drug-Drug Interactions	108
3	Pharmacokinetic Fundamentals	110
3.1	Noncompartmental Analysis of Pharmacokinetic Data	112
3.2	Compartmental Analysis of Pharmacokinetic Data	115
4	Pharmacokinetic Studies in Support of Drug Optimization	116
5	Absorption and Permeability	118
6	Drug Transporters	121
7	Protein Binding	123
7.1	Protein-Binding Theory	123
7.2	Role of f_u in Clearance and Volume of Distribution	125
7.3	Experimental Techniques	126
7.4	Optimization of f_u in Drug Discovery	127
8	Pharmacokinetics and Pharmacodynamics	127
8.1	Reversible Direct Effects	128
8.2	Time-Delayed Effects	131
9	Predicting Human Pharmacokinetics	134
9.1	Importance of Dose	135
10	Summary	137
	References	137

Chapter 5	Cardiovascular Drugs	141
1	Introduction	141
2	Early History of Coronary Heart Disease (CHD)	142
3	Lipid-Lowering Agents	143
3.1	Nicotinic Acid Derivatives	144
3.2	Bile Acid Sequestrants (BAS)	145
3.3	Fibric acids	146
3.4	Probucol	147
3.5	HMG-CoA Reductase Inhibitors	148
3.6	Cholesterol Absorption Inhibitors	152
3.7	Triglyceride-lowering Agents	154
3.8	HDL-Elevating Agents	154
4	Antihypertensive Agents	157
4.1	Early Vasodilators	159
4.2	Autonomic Nervous System (Sympatholytic) Approaches to Hypertension	160
4.3	Diuretics	167
4.4	Calcium Channel Blockers	171
4.5	The Renin-Angiotensin-Aldosterone System (RAAS)	173
4.6	Endothelin Antagonists	180
5	Antithrombotic Drugs	181
5.1	Antiplatelet Agents	182
5.2	Anticoagulant Agents	188
6	Thrombolytic Agents	194
7	Antianginal Agents	195
8	Heart Failure Drugs	195
9	The Future	197
	References	197
Chapter 6	Diabetes Drugs	205
1	Introduction	205
1.1	Homeostasis of Glucose	205
1.2	Diabetes	206
2	Current therapies for Type 2 Diabetes	208
2.1	Biguanides	208
2.2	Insulin Secretagogues: Sulfonylureas and Glinides	210
2.3	α -Glucosidase Inhibitors	213
2.4	PPAR γ Agonists: Thiazolidinediones (TZDs)	213
2.5	Incretin-Based Therapies	216
2.6.	Amylin Analog	219
3	Other Treatments for Type 2 Diabetes	219
3.1	Bile Acid Sequestrants	220

3.2	Orlistat	220
3.3	Bromocriptine	221
4	Novel Mechanisms of Action: Future Treatments for Type 2 Diabetes	221
4.1	Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors	221
4.2	PPARs: Next Generation	224
4.3	Glucokinase Activators	225
4.4	GPR119 Agonists	225
4.5	D-Tagatose	225
4.6	11 β -Hydroxysteroid Dehydrogenase Type 1 (11 β -HSD1) Inhibitors	226
4.7	Diacylglycerol Acyltransferase 1 (DGAT-1) Inhibitors	226
5	Current Therapies for Type 1 Diabetes	226
5.1	Insulin	226
5.2	Insulin Analogs	228
6	Future Treatments for Type 1 Diabetes	232
6.1	Developments in Insulin Area	232
6.2	Approaches to Fight β -cell Destruction	233
7	Future Prospects for New Diabetes Drugs	236
	References	236
Chapter 7	CNS Drugs	245
1.	Introduction	245
2.	Antipsychotic Drugs	246
2.1	Typical Antipsychotics—The First Generation	247
2.2	Atypical Antipsychotics—The Second Generation	248
2.3	Recent Development of Newer Agents	250
3.	Antidepressant Drugs	252
3.1	Monoamine Oxidase Inhibitors (MAOIs)	252
3.2	Tricyclic Antidepressants (TCAs)	253
3.3	Selective Serotonin Reuptake Inhibitors (SSRIs)	254
3.4	Combined Noradrenaline/Serotonin Reuptake Inhibitors (SNRIs)	255
3.5	Novel Approaches	256
4.	Drugs for Epilepsy and Bipolar Disorder	259
4.1	Older Antiepileptics	259
4.2	Newer Antiepileptics	261
5.	Anxiolytic Drugs	263
5.1	Benzodiazepines	263
5.2	Novel Anxiolytics	265
6.	Centrally Acting Analgesic Drugs	266
6.1	Opiates	266

6.2	Miscellaneous CNS Analgesics	268
7.	Drugs for treating Substance Abuse and ADHD	269
7.1	Substance Abuse	269
7.2	Attention Deficit Hyperactivity Disorder (ADHD)	269
8.	Drugs for Neurodegenerative Diseases	271
8.1	Alzheimer's Disease (AD)	271
8.2	Parkinson's Disease (PD)	273
8.3	Huntington's Disease (HD)	275
8.4	Amyotrophic Lateral Sclerosis (ALS)	276
8.5	New Directions in Neurodegenerative Disease	276
9.	Future Prospects for New CNS Drugs	277
	References	278
Chapter 8	Cancer Drugs	287
1	Introduction	287
2	Historical Perspective of Cancer Drugs	289
3	Antimetabolites	290
3.1	Folate Antagonists	291
3.2	Purine and Pyrimidine Antimetabolites	292
4	Alkylating Agents	295
5	Platinum Complexes	298
6	Plant- and Marine-Based Natural Products	299
7	Topoisomerase Inhibitors	304
7.1	Topoisomerase I Inhibitors	305
7.2	Topoisomerase II Inhibitors	307
8	Antitumor Antibiotics	309
9	Tyrosine Kinase Inhibitors (TKIs)	310
9.1	Monoclonal Antibodies	316
10	Hormones	318
10.1	Antiestrogens	318
10.2	Androgens	319
10.3	Aromatase Inhibitors	320
10.4	Gonadotropin-Releasing Hormone Agonists	322
10.5	Gonadotropin-Releasing Hormone Antagonists	324
11	Histone Deacetylase (HDAC) Inhibitors	325
12	Miscellaneous Cancer Drugs	327
13	Conclusion	329
	References	330
Chapter 9	Anti-Inflammatory and Immunomodulatory Drugs	337
1	Introduction	337
1.1	Innate Immune Response	337
1.2	Adaptive Immune Response	338

2	Arachidonic Acid Cascade	343
2.1	Cyclooxygenase (COX) Inhibitors	344
2.2	Cyclooxygenase-2 (COX-2) Inhibitors	345
2.3	Prostaglandin I ₂ (Prostacyclin)	349
2.4	Prostaglandin E ₂	349
2.5	Thromboxane A ₂	350
3	Leukotriene Pathway Inhibitors	351
3.1	5-Lipoxygenase Inhibitors	352
3.2	Leukotriene Receptor Antagonists	353
4	Antihistamines	355
5	Corticosteroids	357
6	Rheumatoid Arthritis	360
6.1	Methotrexate	362
6.2	Sulfasalazine	364
6.3	Minocycline	365
6.4	Hydroxychloroquine	365
6.5	Leflunomide	366
7	Osteoarthritis	367
8	Chronic Inflammatory Arthritis and Gout	368
8.1	Colchicine	368
8.2	Uricosuric Agents	369
8.3	Xanthine Oxidase	369
8.4	Urate Oxidase	370
9	Multiple Sclerosis	370
9.1	Natalizumab (Tysabri)	370
9.2	IFN-Beta	371
9.3	Mitoxantrone	371
9.4	Glatiramer Acetate (Copaxone)	371
9.5	Fingolimod	372
10	Transplantation	372
10.1	Azathioprine	373
10.2	Cyclosporine	373
10.3	Tacrolimus	374
10.4	Sirolimus (Rapamycin)	375
11	Biological Agents That Suppress Cytokine Production or Signaling	376
11.1	Etanercept	376
11.2	Infliximab	376
11.3	Adalimumab	376
11.4	Golimumab	377
11.5	Certolizumab Pegol	377
12	B-Cell Therapy	378
12.1	Rituximab	378

12.2	Ocrelizumab	378
12.3	Ofatumumab	378
12.4	Belimumab	378
13	Cytotoxic T-Lymphocyte Antigen 4 (CTLA4)	379
13.1	Abatacept	379
13.2	Belatacept	379
14	Interleukins	379
14.1	Tocilizumab	379
14.2	Ustekinumab	380
14.3	Anakinra	380
14.4	Canakinumab	381
14.5	Riloncept	381
15	Safety	381
16	Summary	382
	References	382
Chapter 10	Antibacterial Drugs	389
1	Introduction	389
2	The Rise and Decline of Antibiotics	389
3	The Unique Challenges of Antibacterial Drug Discovery	390
3.1	Lead Matter	391
3.2	Bacterial Targets	391
3.3	Resistance	391
3.4	Efflux and Permeability	392
3.5	Lack of Diagnostics	392
3.6	Clinical Trials	392
3.7	Commercial Landscape	393
4	Antibiotic Classes	393
4.1	Cell Wall Biosynthesis Inhibitors	393
4.2	Ribosome Inhibitors	403
4.3	DNA and RNA Synthesis Inhibitors	413
4.4	Membrane Inhibitors	418
5	Emerging Strategies to Discover New Antibacterial Drugs	423
5.1	New Compounds, In or Near the Clinic	423
5.2	Tools for Discovery	423
5.3	Screening	426
5.4	New Targets	426
5.5	Emerging Strategy	427
6	Conclusions	428
	References	428

Chapter 11	Antiviral Drug Discovery	439
1.	Introduction	439
2.	Human Immunodeficiency Virus-1 Inhibitors	444
2.1	HIV-1 Entry Inhibitors	446
2.2	HIV-1 Reverse Transcriptase Inhibitors	449
2.3	HIV-1 Protease Inhibitors	453
2.4	HIV-1 Integrase Inhibitors	458
3.	Hepatitis B Virus Inhibitors	460
4	Hepatitis C Virus Inhibitors	464
4.1	HCV NS3 Protease Inhibitors	464
4.2	HCV NS5B RNA-Dependent RNA Polymerase Inhibitors	467
4.3	Inhibitors of HCV NS5A	474
5	Inhibitors of Respiratory Viruses	
	—Influenza and Respiratory Syncytial Virus	476
5.1	Influenza Virus	476
5.2	Respiratory Syncytial Virus (RSV)	481
6.	Herpesviridae Inhibitors	485
6.1	Herpes Simplex Viruses 1 and 2	486
6.2	Varicella zoster Virus (VZV)	486
6.3	Human Cytomegalovirus (HCMV) Inhibitors	487
6.4	Epstein-Barr virus (EBV, Human Herpesvirus 4) Inhibitors	488
7	Epilogue	489
	References	489
Index		517